NEW YORK, May 6, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Senti Biosciences, Inc. ("Senti" or the "Company") (NASDAQ: SNTI). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.The investigation concerns whether Senti and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action]On April 28, 2025, Senti ...

NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Senti Biosciences, Inc. (“Senti” or the “Company”) (NASDAQ: SNTI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Senti and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On April 28, 2 ...

Kanya Rajangam, MD, PhD, President, Head of R&D and Chief Medical Officer of Senti Bio discusses the positive data from lead program, SENTI-202, recently presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 Watch the “What This Means” segment here SOUTH SAN FRANCISCO, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its ...

Live video webcast presentation on Thursday, May 8th at 1:00 PM ET Presentation will highlight the recently announced positive preliminary clinical results of lead program, SENTI-202, in the treatment of patients with Relapsed/Refractory AML SOUTH SAN FRANCISCO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, ...

NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Senti Biosciences, Inc. (“Senti” or the “Company”) (NASDAQ: SNTI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Senti and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On April 28 ...

Summary of Senti Biosciences Senti-two zero two Clinical Update Conference Call Company and Industry - **Company**: Senti Biosciences - **Industry**: Biotechnology, specifically focused on cell therapy for hematological malignancies, particularly Acute Myeloid Leukemia (AML) Core Points and Arguments 1. **Introduction of Senti-two zero two**: Senti Biosciences is developing SENTI-two zero two, a logic gated CAR NK cell therapy targeting relapsed/refractory AML and related hematological cancers, with promising preliminary results from a Phase one trial [6][7][40]. 2. **Mechanism of Action**: The therapy utilizes a unique logic gate technology that allows for precise targeting of cancer cells while sparing healthy cells, addressing the challenge of heterogeneous cancer cell populations [8][10][14]. 3. **Patient Demographics**: AML affects approximately 21,000 patients annually in the U.S., with a high relapse rate and poor prognosis, highlighting the urgent need for effective therapies [11][12]. 4. **Trial Design**: The Phase one trial is a multi-center, open-label study enrolling adult patients aged 18-75 with relapsed/refractory AML, focusing on safety, maximum tolerated dose (MTD), and efficacy [19][20]. 5. **Dosing and Administration**: The trial evaluates two dose levels of 1 billion and 1.5 billion CAR NK cells, administered in either three or five doses following lymphodepletion [22][23]. 6. **Safety Profile**: Preliminary safety data indicate that SENTI-two zero two is well tolerated, with no dose-limiting toxicities reported and adverse events primarily being hematologic in nature [26][29][40]. 7. **Efficacy Results**: Five out of seven patients achieved an overall response rate (ORR), with four achieving complete remission (CR), indicating promising efficacy in a heavily treated patient population [30][31][40]. 8. **Durability of Response**: All CR patients were minimal residual disease (MRD) negative, with ongoing responses and a median duration of response not yet reached [31][34][41]. 9. **Future Directions**: The company plans to expand the trial to include more patients and potentially explore other malignancies expressing CD33 or FLT3, such as MDS [49][62]. Other Important but Possibly Overlooked Content 1. **Logic Gate Technology**: The logic gate mechanism allows for the recognition of multiple cancer antigens, enhancing the therapy's ability to target diverse cancer cell populations [9][10]. 2. **Patient Characteristics**: The trial population had multiple adverse prognostic factors, including rapid failure of prior therapies and adverse genetic characteristics, underscoring the high unmet need in this patient group [24][25][34]. 3. **Comparison with Existing Therapies**: Current standard care for relapsed/refractory AML shows low response rates (15-25% for CR), emphasizing the need for innovative therapies like SENTI-two zero two [12][65]. 4. **Potential for Outpatient Use**: Given the favorable safety profile of NK cells, there are plans to develop SENTI-two zero two for outpatient administration [50]. 5. **Broader Applications**: The technology has potential applications beyond AML, including solid tumors, which could significantly expand its therapeutic reach [60][61]. This summary encapsulates the key points discussed during the conference call, highlighting the innovative approach of Senti Biosciences in addressing a critical need in cancer treatment.

Data presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 Dose Finding completed with no dose limiting toxicities and preliminary recommended Phase 2 dose (RP2D) identified 5 of 7 best overall response evaluable patients achieved ORR (3 CR, 1 CRh and 1 morphologic leukemia-free state) across all dose cohorts, including 1 CR and 1 CRh in 3 patients in preliminary RP2D cohort 4 of 4 cCR patients were measurable residual disease (MRD) negative as assessed by local standard of ca ...

SOUTH SAN FRANCISCO, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it will host a conference call and webcast to discuss the new SENTI-202 Phase 1 clinical data being presented at the American Association for Cancer Research (AACR) Annual Meeting on Monday, April 28, 2025 at 8:30 AM ET. ...

Company Overview - Senti Biosciences, Inc. is a clinical-stage biotechnology company focused on developing next-generation cell and gene therapies using its proprietary Gene Circuit platform [2][4] - The company aims to create therapies that enhance precision and control in targeting cancer cells while sparing healthy cells [4] Lead Program - Senti Bio's lead program, SENTI-202, targets hematologic cancers by focusing on CD33 and/or FLT3 [4] - SENTI-202 is currently enrolling patients in a Phase I clinical trial, indicating progress in clinical development [4] Research and Development - The company has demonstrated preclinical success with its Gene Circuits in T cells, enabling selective targeting of solid tumors [4] - Senti Bio is advancing its capabilities through partnerships and exploring applications of Gene Circuits in other cell and gene therapy modalities beyond oncology [4] Industry Context - The discussion in the Virtual Investor KOL segment highlighted the current treatment landscape for acute myeloid leukemia (AML) and areas of unmet need [3] - The insights from respected leukemia researcher Stephen Strickland, MD, emphasize the significance of Senti Bio's innovative approach in addressing these unmet needs [3]

Live moderated webcast with members of the Senti Bio management team on Wednesday, April 23rd at 4:00 PM ETSOUTH SAN FRANCISCO, Calif., April 16, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that will participate in the Virtual Investor Closing Bell Series on Wednesday, April 23, 2025 at 4:00 PM ET. As part o ...